CEL-SCI Corp (CVM)

20.91
-0.44(-2.06%)
After Hours
20.91
0.00(0.00%)
- Real-time Data
  • Volume:
    541,014
  • Bid/Ask:
    20.91/21.50
  • Day's Range:
    20.70 - 21.75

CVM Overview

Prev. Close
21.35
Day's Range
20.7-21.75
Revenue
230K
Open
21.75
52 wk Range
10.76-40.91
EPS
-0.91
Volume
541,014
Market Cap
891.41M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
976,342
P/E Ratio
-
Beta
2.23
1-Year Change
65.25%
Shares Outstanding
42,529,065
Next Earnings Date
Aug 17, 2021
What is your sentiment on CEL-SCI Corp?
or
Market is currently closed. Voting is open during market hours.

CEL-SCI Corp News

  • Cel-Sci reports FQ2 results
    • BySeeking Alpha-

    Cel-Sci (CVM): FQ2 GAAP EPS of -$0.28.Cash and cash equivalentsof $6.43MShares +0.64% PM.10QPress Release

  • Midday Gainers / Losers (09/14/2018)
    • BySeeking Alpha-

    Gainers: MYSZ +27%. KNDI +21%. LYL +20%. FEIM +18%. CSBR +17%. CVM +14%. BLBD +13%. VHC +12%. OXBR +13%. UBX +11%. Losers: IRIX -15%. WAB -11%. SRNE -10%. PETZ -10%. NI -10%....

CEL-SCI Corp Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellSellBuy
Technical IndicatorsStrong SellStrong SellStrong SellStrong SellStrong Buy
SummaryStrong SellStrong SellStrong SellStrong SellStrong Buy

CEL-SCI Corp Company Profile

CEL-SCI Corp Company Profile

Employees
43

CEL-SCI Corporation is engaged in the research and development at developing the treatment of cancer and other diseases by using the immune system. The Company is focused on activating the immune system to fight cancer and infectious diseases. It operates through the segment of research and development of certain drugs and vaccines. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), an investigational immunotherapy under development for treatment of certain head and neck cancers, and anal warts or cervical dysplasia in human immunodeficiency virus and human papillomavirus co-infected patients and Ligand Epitope Antigen Presentation System (L.E.A.P.S.) technology, with over two investigational therapies, LEAPS-H1N1-DC, a product candidate under development for treatment of pandemic influenza in hospitalized patients, and CEL-2000 and CEL-4000, vaccine product candidates under development for treatment of rheumatoid arthritis.

Read More
  • x10 bagger with the next 60 days.
    0
    • when will the good news released and what time?
      0
      • Price target?
        0
        • 60
          0
          • Fly!!!
            1
            • Tomorrow Green!!
              1
              • it will go up to 40 before end of day
                2
                • $80 by April 1, 2021
                  0
                  • This is a $200 stock if Phase 3 is positive. Data is currently locked and phase 3 is imminent  Worthwhile taking a risk!!
                    0
                    • over sold
                      1
                      • approaching a new 52 week high
                        0
                        • New 52 week high. Less than 7 day til July 1 Russell 3k
                          0
                          • retesting the $8 resistance after July 1 Russell index volume and exposure will increase
                            0
                            • retesting $7
                              0
                              • This stock might finally be paying off...only took 30 years...MK might, just might, be the real deal.
                                0
                                • This stock might finally be paying off...only took 30 years...MK might, just might, be the real deal.
                                  0
                                  Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                                  Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.